|

Efficacy of the Use of Vasopressin as a Primary Vasoconstrictor in Critically Ill Patients

RECRUITINGPhase 4Sponsored by University of Thessaly
Actively Recruiting
PhasePhase 4
SponsorUniversity of Thessaly
Started2023-12-15
Est. completion2025-12-31
Eligibility
Age18 Years+
Healthy vol.Accepted

Summary

Current guidelines recommend the inititaion of noradrenaline and if shock is refractory, then vasopressin should be administered. Data indicate that the earlier use of vasopressin may improve survival. Two large randomized controlled trial failed to prove a survival benefit from the early use of vasopressin. The present study will investigate the effect of an early initiation protocol of vasopressin (as the first vasoconstrictor drug) on the degree of multiorgan failure improvement and also on the course of sepsis (if in septic patients) versus early initiation of noradrenaline as first vasoconstrictor drug in hemodynamically unstable patients.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

• Shock (mean arterial pressure \<65 mmHg) after initial resuscitation with fluids

Exclusion Criteria:

* Patients under 18 years of age.
* Known heart failure (ejection fraction \&lt;35%)
* Recent acute myocardial infarction
* Pulmonary embolism

Conditions2

Circulatory ShockDiabetes

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.